HC Wainwright Forecasts Kodiak Sciences Q1 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Kodiak Sciences in a report issued on Monday, March 31st. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.90) per share for the quarter. HC Wainwright has a "Neutral" rating and a $3.00 price target on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' FY2029 earnings at ($1.51) EPS.

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price objective for the company in a report on Monday, December 9th.

Kodiak Sciences Price Performance

KOD stock traded down $0.05 during trading hours on Wednesday, reaching $2.35. 541,890 shares of the stock were exchanged, compared to its average volume of 345,247. The company has a market cap of $123.96 million, a price-to-earnings ratio of -0.64 and a beta of 2.40. The firm's 50-day moving average is $4.44 and its 200-day moving average is $5.41. Kodiak Sciences has a 12 month low of $2.11 and a 12 month high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.06.

Remove Ads

Institutional Trading of Kodiak Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its holdings in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after purchasing an additional 2,988 shares during the period. American Century Companies Inc. raised its stake in Kodiak Sciences by 6.2% in the 4th quarter. American Century Companies Inc. now owns 59,967 shares of the company's stock valued at $597,000 after acquiring an additional 3,515 shares during the period. US Bancorp DE acquired a new stake in Kodiak Sciences during the 4th quarter valued at $40,000. Bank of New York Mellon Corp boosted its position in Kodiak Sciences by 5.3% during the fourth quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock worth $976,000 after purchasing an additional 4,927 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Kodiak Sciences by 2.9% in the fourth quarter. Northern Trust Corp now owns 269,597 shares of the company's stock valued at $2,682,000 after purchasing an additional 7,678 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.